Thit M Kronborg, Robert Schierwagen, Kajetan Trošt, Qian Gao, Thomas Moritz, Flemming Bendtsen, Rasmus H Gantzel, Mette L Andersen, Ane S Teisner, Henning Grønbæk, Lise Hobolth, Søren Møller, Jonel Trebicka, Nina Kimer
BACKGROUND: Patients with cirrhosis and portal hypertension face a high risk of complications. Besides their anti-inflammatory and antifibrotic effects, statins may reduce portal pressure and thus the risk of complications and mortality. We aimed to investigate the effects of atorvastatin on hospital admissions, mortality, inflammation, and lipidomics in cirrhosis with portal hypertension. METHODS: We performed a double-blinded, randomized, placebo-controlled clinical trial among patients with cirrhosis and portal hypertension...
December 1, 2023: Hepatology Communications